Dr. Michael Har-Noy, CEO of Immunovative Therapies, Ltd. discusses how a 12-year-old Great Dane presenting with bronchoalveolar cancer, with a life expectancy 1 month or less, lived over 50 weeks post-diagnosis after being given Immunovative Therapies, Ltd.'s chaperone-rich-cell-lysate (CRCL).
Before treatment by Dr. Michael Har-Noy of Immunovative Therapies, Ltd., the Great Dane presented with nystagmus and collapse. Chest X-rays showed a lesion in the right lung. Ultrasound-guided needle biopsy demonstrated bronchoalveolar adenocarcinoma, and the canine underwent thoracotomy with lobectomy. The pathology analysis showed grade III bronchoalveolar adenocarcinoma with nodal metastases and blood vessel involvement. The average survival for this cancer is less than 1 month.
Using Dr. Michael Har-Noy's unique methods, a piece of the cancer was formulated into a CRCL vaccine, which was given weekly to the animal. Also, Imiquimod - a Toll-like receptor 7 agonist - was given to the animal for twelve treatments to stimulate Langerhans cells. Furthermore, the dog was given a single bacillus Calmette-Guerin shot at 30 weeks of treatment to further augment its immune mechanism.
The Great Dane remained good health until the cancer recurred during the 44th post-treatment week with Dr. Michael Har-Noy's CRCL compound. The dog then went on to have severe gastrointestinal bleeding and had to be euthanized at just beyond 50 weeks after the original diagnosis.
Dr. Michael Har-Noy indicates that this is the first report of significantly improved outcome following a diagnosis of grade III/stage III bronchoalveolar adenocarcinoma in a dog. This indicates that Dr. Michael Har-Noy's CRCL vaccine, when used with Imiquimod, is a safe and very efficacious therapy for canine malignancy.
Dr. Michael Har-Noy founded Immunovative Therapies Ltd. in Israel in 2004. Immunovative Therapies, Ltd. manufactures unique drugs that manipulate a patient's immune system and enable it to eradicate malignant cells.